Kimberly Fisher

The meeting agenda includes administrative matters such as roll call and conflict of interest statements, as well as health plan policy discussion and an annual by-law review. Key substantive topics involve elections and a deep review of past interventions regarding Opioids and Antipsychotics (December 2024), The "Holy Trinity" (January 2025), and HFrEF without ACE/ARB (February 2025). Recent interventions scheduled for review include Diabetes without Statin (October 2025) and Atrial Fibrillation without Anticoagulation (November 2025). A new intervention concerning Benzodiazepine Monotherapy for February 2026 is also planned. Reports are expected from the DUR Committee and regarding the Monthly MAT + Opioid Program, followed by announcements and calendar review.

This Population Health and Quality Strategy for the Ohio Department of Medicaid provides a comprehensive roadmap for improving healthcare quality and services for Medicaid beneficiaries from 2026 to 2028. It focuses on five programmatic goals: improving wellness and health outcomes, emphasizing personalized care, supporting providers, enhancing care for individuals with complex needs, and increasing program transparency and accountability. The strategy addresses five population health streams: Healthy Children and Adults, Women and Infant Health, Behavioral Health, Chronic Physical and Developmental Conditions, and Older Adults, aiming to ensure all beneficiaries receive appropriate, timely, and positive healthcare.

The meeting included a health plan policy update, a review and approval of previous DUR Board meeting minutes, and an open discussion on various topics, including HIV medication adherence, long-term benzodiazepine use, appropriate antiplatelet use, pediatric opioid prescribing, and opioids for dental pain. There was also a discussion on gabapentin use and re-reviews of interventions related to CKD without ACE/ARB, HFREF without Beta Blocker, and Stimulants and CVD. Recent interventions on Benzodiazepines and High Dose-Opioids, Anticholinergic Adverse Effects, and Migraine Prophylaxis were presented, along with a new intervention on Atrial Fibrillation without Anticoagulation. The Monthly Medication-Assisted Treatment (MAT) Report for October 2025 and the Coordinated Services Program Report were also presented. Announcements included the upcoming voting for chair and vice chair positions and a review of the bylaws at the February meeting. The 2025 intervention calendar and future meeting dates were reviewed.

The meeting included a report of Drug-Drug Interactions for Board consideration and discussion regarding appropriate drug-drug interactions that should message in the new claims processing system. Elections for Chair and Vice Chair were held. The Board discussed the meeting schedule for the remainder of 2016.

The meeting included a health plan policy update regarding age restrictions on codeine and tramadol, ODM staffing updates, and a review of the CMS Drug Utilization Review Annual Report for federal fiscal year 2024. The DUR Committee presented re-reviews of interventions, including stimulant and benzodiazepine co-prescribing, frequent SABA use, and antipsychotic metabolic monitoring. Recent interventions discussed were related to the "Holy Trinity" combination, heart failure without ACE/ARB, and Montelukast boxed warning. A new intervention on COPD Controller Inhalers was also presented. The meeting also covered the Monthly Medication-Assisted Treatment (MAT) Report for April 2025 and the Coordinated Services Program Report.